Crescent Biopharma, Inc.
NASDAQ:CBIOBiotechnology
-$0.49 today
- Market cap
- $482.30M
- Beta
- 1.15
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$5.33
Volume 0.33M
Average 0.28M
CBIO EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Crescent Biopharma, Inc.NASDAQ: CBIO
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$23.22M, compared with -$14.04M a year earlier. Trailing-twelve-month EBITDA was -$158.86M.
Context
- EBITDA amounted to 1380.2% of revenue in FY2025.
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of -$33.68M (+77.5%) for the fiscal year ending Dec 2026, a step up from the -238.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$23.22M+74.3% QoQ
- Last fiscal yearDec 2025
- -$149.67M-238.8% YoY
- LTMMar 2026
- -$158.86M-1227.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -65.4% | -38.4% | +27.0 pp |
| 1 year | -238.8% | +77.5% | +316.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (149.67M) USD
- Year-over-year change
- -238.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (149.67M) | -238.8% |
| FY2024 | 2024-12-31 | (44.17M) | -12.9% |
| FY2023 | 2023-12-31 | (39.12M) | +17.1% |
| FY2022 | 2022-12-31 | (47.2M) | +25.3% |
| FY2021 | 2021-12-31 | (63.18M) | — |
EBITDA vs competitors
How CBIO compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -1227.0% is the lowest of 10, against a peer median of -25.2%.
- EBITDA amounts to 1336.8% of revenue for CBIO, versus a peer median of 105.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $57.08M USD | +205.8% | — | 21.5% | |
| LTM Mar 2026 | $34.88M USD | +463.6% | — | 48.0% | |
NBPNovaBridge Biosciences | LTM Sep 2025 | -CN¥33.25M CNY | +92.9% | — | — |
| LTM Mar 2026 | -$40.18M USD | -45.5% | — | — | |
| LTM Mar 2026 | -$50.64M USD | -7.0% | — | 32.2% | |
| LTM Mar 2026 | -$57.67M USD | -232.5% | — | 162.2% | |
| LTM Mar 2026 | -$67.05M USD | -25.2% | — | — | |
| LTM Mar 2026 | -$158.86M USD | -1227.0% | — | 1336.8% | |
| LTM Sep 2026 | -$305.37M USD | -38.1% | — | 272652.7% | |
| LTM Jun 2026 | -$419M USD | -48.6% | — | 358.1% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CBIO) | — | -25.2% | — | 105.1% | |
Competitors are the stored peer set for CBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.16M | 75K | 10K | 0 | 10.84M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 1.16M | 75K | 10K | 0 | 10.84M |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | 100.0% |
| Research & Development | 47.49M | 28.39M | 20.07M | 28.06M | 138.09M |
| Selling, General & Admin | 17.12M | 19.09M | 19.21M | 16.32M | 25.39M |
| Operating Expenses | 64.61M | 47.48M | 39.29M | 49.9M | 163.48M |
| Depreciation & Amortization | 264.6K | 207.15K | 153.3K | 35.17K | 84K |
| EBITDA | (63.18M) | (47.2M) | (39.12M) | (44.17M) | (149.67M) |
| EBITDA Margin | -5447.9% | -62927.6% | -391213.5% | — | -1380.2% |
| Operating Income | (63.45M) | (47.4M) | (39.28M) | (49.9M) | (152.63M) |
| Operating Margin | -5470.7% | -63204.4% | -392752.9% | — | -1407.5% |
| Interest Income | 19.77K | 714.52K | 2.38M | 1M | 2.88M |
| Interest Expense | 0 | 0 | 0 | 852K | 2.19M |
| Other Income / Expenses | 19.77K | 714.96K | 2.38M | 1.37M | 690K |
| Income Before Tax | (63.43M) | (46.69M) | (36.9M) | (48.52M) | (151.94M) |
| Pre-Tax Margin | -5469.0% | -62251.1% | -368987.8% | — | -1401.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 2M |
| Net Income | (63.43M) | (46.69M) | (36.9M) | (48.52M) | (153.94M) |
| Net Margin | -5469.0% | -62251.7% | -368994.2% | — | -1419.6% |
| EPS (Basic) | (1.23) | (0.89) | (0.58) | (1.40) | (14.78) |
| EPS (Diluted) | (1.23) | (0.89) | (0.58) | (1.40) | (14.78) |
| Weighted Avg Shares | 51.45M | 52.53M | 63.34M | 19.5M | 10.41M |
| Weighted Avg Shares (Diluted) | 51.45M | 52.53M | 63.34M | 19.5M | 10.41M |
Crescent Biopharma, Inc.
NASDAQ:CBIO
Intrinsic Alpha fair value
Locked
Current Price
$12.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.